Division of DaVita HealthCare Partners Inc.
Latest From DaVita Labs
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
The company is shipping Neutrolin, a device containing an antimicrobial/antifungal agent and two anti-clotting agents, in Germany to “lock” catheters between dialysis sessions and prevent blood stream infections and clots. The New Jersey firm also is working with FDA to get the product approved in the U.S. as a specialty pharmaceutical.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity.
- Laboratory Testing Services
- Therapeutic Areas
- Renal System
- North America
- Parent & Subsidiaries
- DaVita HealthCare Partners Inc.
- Senior Management
Chris Rucker, Pres.
Valerie Nahay, VP, Sales & Mktg.
Teri White, VP, Fin.
- Contact Info
Phone: (877) 200-3181
3951 SW 30th Ave.
Fort Lauderdale, FL 33312
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.